Vera Therapeutics, Inc.’s VERA share price has surged by 6.17%, which has investors questioning if this is right time to sell.

Protagonist Therapeutics, Inc. (”Protagonist” or the “Company”) announced that an abstract was accepted for presentation at the Plenary Session at the American Society of Clinical Oncology (ASCO) ...

Our round-up of recent biotech financings is headed by a $250 million public offering for late clinical-stage biotech Vera Therapeutics, with an initial public offering (IPO) filed by CAR-T ...

Groundbreaking longevity research initiative brings together leading scientists and institutions to decode the genetic basis ...

Dr. Vera will join company executives and key opinion leaders to discus HOUSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology ...

Ratio also said that biopharma industry veteran Susan Whoriskey - a member of the founding executive teams of Vera Therapeutics, Moderna, Momenta Pharmaceuticals, and Cubist Pharmaceuticals ...

Incyte Corporation INCY is expected to beat estimates when it reports first-quarter 2025 earnings results on April 29, before ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

Verastem Oncology (NASDAQ:VSTM) announced on Wednesday that the U.S. FDA has cleared the investigational new drug application ...

Today, the American Kidney Fund (AKF) announces its 2025 Class of Corporate Members who serve as strategic partners in AKF's Corporate Membership Program. Corporate Members provide vital support to ...